Greg Jones
Company: Pfizer
Job title: Principle Scientist, Team Leader
Seminars:
Live Panel Q&A – Ask the Speakers Your Burning Questions 3:15 pm
day: Day Two
Live Panel Q&A – Ask the Speakers Your Burning Questions 12:50 pm
day: Day Two
Multi-Omics Data Integration Reveals Emerging Targets for RAS Mutant Cancers 2:50 pm
Targeting KRAS has proven clinical value for G12C mutant tumors – can this be expanded by a new wave of target ID, with distinct activity in intrinsic or acquired resistant models to G12C inhibition? Utilizing a combination of KRASG12Ci Resistant cell line models, and in vivo CRISPR drop out screens, reveals new targets required for…Read more
day: Day Two
Panel Discussion: Revealing Signaling Vulnerabilities: Reviewing Emerging Targets for RAS Mutated Cancers 2:40 pm
As the landscape of approaches targeting RAS mutated cancers continues to grow, there are a whole host of investigational inhibitors focused on targeting the RAS signaling pathway and the high value targets which exist within. Now more than ever, it is critical to understand the regulatory mechanisms downstream and upstream of RAS and consider the…Read more
day: Day One